What is claimed is:

1. Use of at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (rilzabrutinib) and pharmaceutically acceptable salts thereof in the manufacture of a medicament for treating chronic spontaneous urticaria (CSU) in a human patient in need thereof, wherein the medicament is to be administered to the human patient in a therapeutically effective amount for a treatment period.

2. The use of claim 1, wherein at least one of the following occurs:
   (a) the human patient has moderate-to-severe CSU;
   (b) the human patient has moderate CSU;
   (c) the human patient has severe CSU.

3. The use of claim 1 or claim 2, wherein the human patient has CSU refractory to H1 antihistamine (H1-AH) treatment.

4. The use of any one of claims 1-3, wherein the human patient has Type I autoimmune CSU.

5. The use of any one of claims 1-3, wherein the human patient has Type IIb autoimmune CSU.

6. The use of any one of claims 1-5, wherein the human patient has angioedema.

7. The use of any one of claims 1-6, wherein at least one of the following occurs:
   (a) the human patient achieves a Urticaria Activity Score (UAS7) that is lower than baseline UAS7;
   (b) the human patient achieves a UAS7 that is lower than baseline UAS7 within 52 weeks of initiating rilzabrutinib treatment;
   (c) the human patient achieves a UAS7 that is lower than baseline UAS7 within 24

weeks of initiating rilzabrutinib treatment;

(d) the human patient achieves a UAS7 that is lower than baseline UAS7 within 12 weeks of initiating rilzabrutinib treatment;

(e) the human patient achieves a UAS7 that is lower than baseline UAS7 within 4 weeks of initiating rilzabrutinib treatment;

(f) the human patient achieves a UAS7 ≤6;

(g) the human patient achieves a UAS7 ≤6 within 12 weeks of initiating rilzabrutinib treatment;

(h) the human patient achieves a UAS7 of 0;

(i) the human patient achieves a UAS7 of 0 within 12 weeks of initiating rilzabrutinib treatment;

(j) the human patient achieves a UAS7 that is at least 10 points lower than baseline UAS7.

8. The use of any one of claims 1-7, wherein at least one of the following occurs:

(a) the human patient achieves an Itch Severity Score (ISS7) that is lower than baseline ISS7;

(b) the human patient achieves an ISS7 that is lower than baseline ISS7 within 52 weeks of initiating rilzabrutinib treatment;

(c) the human patient achieves an ISS7 that is lower than baseline ISS7 within 24 weeks of initiating rilzabrutinib treatment;

(d) the human patient achieves an ISS7 that is lower than baseline ISS7 within 12 weeks of initiating rilzabrutinib treatment;

(e) the human patient achieves an ISS7 that is at least 5 points lower than baseline ISS7.

9. The use of any one of claims 1-8, wherein at least one of the following occurs:

(a) the human patient achieves a Hives Severity Score (HSS7) that is lower than baseline HSS7;

(b) the human patient achieves a HSS7 that is lower than baseline HSS7 within 52

weeks of initiating rilzabrutinib treatment;

(c) the human patient achieves a HSS7 that is lower than baseline HSS7 within 24 weeks of initiating rilzabrutinib treatment;

(d) the human patient achieves a HSS7 that is lower than baseline HSS7 within 12 weeks of initiating rilzabrutinib treatment.

10. The use of any one of claims 1-9, wherein at least one of the following occurs:

(a) the human patient achieves an Angioedema Activity Score (AAS7) that is lower than baseline AAS7;

(b) the human patient achieves an AAS7 that is lower than baseline AAS7 within 52 weeks of initiating rilzabrutinib treatment;

(c) the human patient achieves an AAS7 that is lower than baseline AAS7 within 24 weeks of initiating rilzabrutinib treatment;

(d) the human patient achieves an AAS7 that is lower than baseline AAS7 within 12 weeks of initiating rilzabrutinib treatment;

(e) the human patient achieves an AAS7 of 0;

(f) the human patient achieves an AAS7 of 0 within 1 week of initiating rilzabrutinib treatment;

(g) the human patient achieves an AAS7 of 0 within 12 weeks of initiating rilzabrutinib treatment.

11. The use of any one of claims 1-10, wherein at least one of the following occurs:

(a) the human patient achieves a Urticaria Control Test (UCT) score that is higher than baseline UCT score;

(b) the human patient achieves a UCT score that is higher than baseline UCT score within 52 weeks of initiating rilzabrutinib treatment;

(c) the human patient achieves a UCT score that is higher than baseline UCT score within 24 weeks of initiating rilzabrutinib treatment;

(d) the human patient achieves a UCT score that is higher than baseline UCT score within 12 weeks of initiating rilzabrutinib treatment;

(e) the human patient achieves a UCT score that is higher than baseline UCT score within 8 weeks of initiating rilzabrutinib treatment;

(f) the human patient achieves a UCT score that is higher than baseline UCT score within 4 weeks of initiating rilzabrutinib treatment;

(g) the human patient achieves a UCT score ≥12;

(h) the human patient achieves a UCT score ≥12 within 12 weeks of initiating rilzabrutinib treatment;

(i) the human patient achieves a UCT score ≥12 within 8 weeks of initiating rilzabrutinib treatment;

(j) the human patient achieves a UCT score ≥12 within 4 weeks of initiating rilzabrutinib treatment.

12. The use of any one of claims 1-11, wherein at least one of the following occurs:

(a) the human patient achieves a change from baseline in health-related quality-of-life (HRQoL);

(b) the human patient achieves a change from baseline in HRQoL as measured by the Patient Global Impression of Severity (PGIS);

(c) the human patient achieves a change from baseline in HRQoL as measured by the PGIS within 12 weeks of initiating rilzabrutinib treatment;

(d) the human patient achieves a change from baseline in HRQoL as measured by the PGIS within 8 weeks of initiating rilzabrutinib treatment;

(e) the human patient achieves a change from baseline in HRQoL as measured by the PGIS within 4 weeks of initiating rilzabrutinib treatment;

(f) the human patient achieves a change from baseline in HRQoL as measured by the PGIS within 2 weeks of initiating rilzabrutinib treatment;

(g) the human patient achieves a change from baseline in HRQoL as measured by the Patient Global Impression of Change (PGIC);

(h) the human patient achieves a change from baseline in HRQoL as measured by the PGIC within 12 weeks of initiating rilzabrutinib treatment;

(i) the human patient achieves a change from baseline in HRQoL as measured by the PGIC within 8 weeks of initiating rilzabrutinib treatment;

(j) the human patient achieves a change from baseline in HRQoL as measured by the PGIC within 4 weeks of initiating rilzabrutinib treatment;

(k) the human patient achieves a change from baseline in HRQoL as measured by the PGIC within 2 weeks of initiating rilzabrutinib treatment.

13. The use of any one of claims 1-12, wherein at least one of the following occurs:

(a) the human patient requires rescue therapy;

(b) the human patient requires rescue therapy and the total number of days for which the human patient requires rescue therapy is lower than the total number of days for which the human patient required rescue therapy during a baseline time period of the same length.

14. The use of any one of claims 1-13, wherein at least one of the following occurs:

(a) the human patient has a history of taking omalizumab prior to the start of the treatment period;

(b) the human patient has had an incomplete response to omalizumab.

15. The use of any one of claims 1-13, wherein the human patient is omalizumab naïve.

16. The use of any one of claims 1-15, wherein at least one of the following occurs:

(a) the human patient has a positive basophil histamine release assay (BHRA) status;

(b) the human patient is to be administered concomitant treatment with an H1-AH;

(c) the treatment period is at least 12 weeks;

(d) the treatment period is at least 52 weeks.

17. The use of any one of claims 1-16, wherein:

(a) the human patient is to be administered 400 mg of the at least one compound chosen from rilzabrutinib and pharmaceutically acceptable salts thereof; or

(b) the human patient is to be administered 400 mg of the at least one compound chosen from rilzabrutinib and pharmaceutically acceptable salts thereof, wherein:

(i) the at least one compound consists of at least one compound chosen from the (E) isomer of rilzabrutinib and pharmaceutically acceptable salts thereof;

(ii) the at least one compound consists of at least one compound chosen from the (Z) isomer of rilzabrutinib and pharmaceutically acceptable salts thereof;

(iii) the at least one compound consists of a mixture of (E) and (Z) isomers of rilzabrutinib or a pharmaceutically acceptable salt of the foregoing.

18. The use of any one of claims 1-17, wherein:

(a) the human patient is to be administered rilzabrutinib once, twice, or thrice a day;

(b) the human patient is to be administered rilzabrutinib once, twice, or thrice a day, wherein:

(i) the at least one compound is the (E) isomer of rilzabrutinib;

(ii) the at least one compound is the (Z) isomer of rilzabrutinib.;

(iii) the at least one compound consists of a mixture of (E) and (Z) isomers of rilzabrutinib;

(c) the human patient is to be administered 400 mg of rilzabrutinib once, twice, or thrice a day.

19. The use of any one of claims 1-17, wherein at least one of the following occurs:

(a) the human patient is to be administered the at least one compound orally;

(b) the human patient is to be administered the at least one compound in in the form of at least one tablet;

(c) the human patient is to be administered the at least one compound with water.